HBx促进ZO1的泛素化降解增加肝癌细胞迁移与侵袭

来源 :中华肝脏病杂志 | 被引量 : 0次 | 上传用户:wanghai19881016
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
目的:研究乙型肝炎病毒X蛋白(HBx)对HepG2细胞ZO1表达水平的影响及闭锁小带蛋白1(ZO-1)对肝癌细胞迁移和侵袭的作用。方法:分别转染HBV全基因质粒(pcDNA3.1-HBV1.1或pcDNA3.1-HBV1.3)、空载质粒(pcDNA3.1)和HBV编码蛋白质粒(pHBc、pHBs、pHBp、pHBx)至肝癌细胞,蛋白质印迹法(Western blot)和RT-PCR检测细胞中ZO1蛋白水平及mRNA水平;转染pHBx,免疫共沉淀和Western blot检测ZO1泛素化水平,Transwell小室检测细胞的迁移与侵袭。转染靶向ZO1的siRNA,乳酸脱氢酶实验检测细胞的增殖,流式细胞术检测细胞的凋亡及周期,Transwell小室检测细胞的迁移与侵袭。两组数据间比较用独立样本n t检验,多组数据比较用单因素方差分析。n 结果:瞬时转染pHBV1.1和pHBV1.3后,相较于空载体对照,HepG2细胞中ZO1的蛋白水平分别下降了42.99%±6.8%和55.0%5±4.56%,其mRNA水平无显著变化;Huh7细胞中ZO1的蛋白水平分别下降了17.46%±4.94%和47.53%±3.38%。转染pHBx后,ZO1蛋白水平下降了47.02%±3.4%,而转染pHBc、pHBs和pHBp后ZO1蛋白水平比较,差异无统计学意义。转染pHBx未影响ZO1的mRNA水平。转染pHBx导致HepG2细胞中ZO1泛素化水平显著增加,细胞迁移和侵袭能力增强。转染靶向ZO1的siRNA后HepG2细胞的增殖、凋亡和周期无明显变化,而迁移和侵袭能力显著升高。结论:HBx可通过促进ZO1蛋白的泛素化降解,增加肝癌细胞的迁移与侵袭。“,”Objective:To study the effect of hepatitis B virus X protein (HBx) expression level on migration and invasion of zonula occludens protein-1 (ZO-1) in HepG2 liver cancer cells.Methods:Liver cancer cells were transfected with HBV full gene plasmid (pcDNA3.1-HBV1. 1 or pcDNA3.1-HBV1.3), empty plasmid (pcDNA3.1) and HBV-encoded protein plasmids (pHBc, pHBs, pHBp and pHBx), respectively. Western blot and RT-PCR were used to detect ZO1 protein and mRNA levels. Immunoprecipitation was used to detect transfected pHBx. Western blot was used to detect ZO1 ubiquitination levels. Transwell chambers were used to assess cell migration and invasion. Cell proliferation and lactate dehydrogenase assay was used to detect siRNA transfecting targeting ZO1. Flow cytometry was used to detect cell apoptosis and cycle. The data was compared between two and multiple groups by using an independent sample t-test and one-way analysis of variance.Results:Compared with the empty plasmid, ZO1 protein level in HepG2 cells after transiently transfected with pHBV1.1 and pHBV1.3 was decreased by 42.99% ± 6.8% and 55.0% 5 ± 4.56%, respectively, and their mRNA levels did not change significantly. ZO1 protein level in Huh7 cells was decreased by 17.46% ± 4.94% and 47.53% ± 3.38%, respectively. ZO1 protein level after transfection with pHBx was decreased by 47.02% ± 3.4%, while the ZO1 protein level after transfection with pHBc, pHBs and pHBp did not change significantly. ZO1 mRNA level was unaffected with pHBx transfection. ZO1 ubiquitin level and cell migration and invasion ability in HepG2 cells was significantly increased with transfected pHBx. HepG2 cells proliferation, apoptosis and cycle after transfection with ZO1-targeted siRNA did not change significantly, but the migration and invasion ability were significantly increased.Conclusion:HBx can increase the migration and invasion of liver cancer cells by promoting the ubiquitination and degradation of ZO1 protein level.
其他文献
临床研究证实慢性乙型肝炎患者接受核苷(酸)类似物抗病毒治疗过程中存在的低水平病毒血症与多种临床不良结局相关。随着PCR检测水平的提升,高灵敏度PCR技术的HBV DNA检测下限可达到<5~10 IU/ml。以HBV DNA < 20 IU/ml为判断标准获得完全病毒学应答者中,采用更高灵敏度PCR技术仍可发现部分患者存在极低水平的病毒血症(HBV DNA 5~10 IU/ml)。长期存在的极低水平病毒血症是否影响慢性乙型肝炎患者的临床结局,目前相关研究较少,需要积累更多的研究数据回答这一临床问题。“,”C
慢性乙型肝炎患者抗病毒治疗后低病毒血症逐渐引起重视,其与肝纤维化进展、肝细胞癌发生和长期生存率降低相关。作为疾病进展的危险因素,在抗病毒治疗中,应对低病毒血症进行干预,以实现完全病毒学应答,改善患者长期预后。“,”Low-level viremia after antiviral therapy has gradually attracted attention due to its relation to liver fibrosis progression, hepatocellular carcin
一线抗病毒药物核苷(酸)类似物(NAs)能够有效抑制HBV复制,减缓慢性乙型肝炎进程,但仍约有20%的接受规范NAs抗病毒治疗的患者会发生低病毒血症(LLV)。厘清LLV发生的机制将有助于优化慢性乙型肝炎患者抗病毒治疗方案,改善患者的预后。系统总结LLV发生的可能机制,认为除了NAs竞争性抑制病毒复制所特有的局限性外,宿主较弱的免疫应答使其直接清除感染肝细胞的能力不足,难以诱发残余感染肝细胞的活跃代偿性增殖及伴随的共价闭合环状DNA池被有效清除或稀释,可能也是NAs在部分患者中无法实现完全病毒学应答的重要
目的:探讨血浆高尔基体蛋白73(GP73)水平与非酒精性脂肪性肝病(NAFLD)发生和发展的关系,并以此为基础联合脂代谢指标建立诊断模型,明确其诊断NAFLD的效能及临床应用价值。方法:选择河北医科大学第三医院中西医结合肝病科及体检中心经超声及肝脏瞬时弹性成像(FibroScan502)检测(部分患者行肝活组织病理学检查)确诊的NAFLD患者225例,健康对照组108名。收集患者临床资料、外周血常规及血清生物化学检测结果。血浆GP73水平采用酶联免疫吸附法检测。应用SPSS 21.0统计学软件进行统计学分
2021年10月召开的Baveno Ⅶ共识会的主题是“门静脉高压的个体化治疗”。主要讨论了9个主题,包括:把测量肝静脉压力梯度作为诊断金标准;非侵入性方法诊断代偿进展期慢性肝病和临床有意义的门静脉高压;病因治疗和非病因治疗对肝硬化的影响;预防首次失代偿;急性静脉曲张出血;预防进一步失代偿;以及内脏静脉血栓和其他肝脏血管病。本文对上述主题的推荐进行编译汇总,把国际上门静脉高压最前沿的研究成果和借此形成的共识意见呈现给读者。“,”The Baveno VII workshop held in October
目的:探讨miRNA-181a(miR-181a)对非酒精性脂肪性肝病的影响及其可能的机制。方法:使用棕榈酸处理HepG2细胞构建非酒精性脂肪性肝病细胞模型,检测细胞内miR-181a的表达及脂质沉积。用转化生长因子-β处理细胞检测其对miR-181a表达的影响。通过调控HepG2细胞miR-181a的表达水平,分别检测转染miR-181a模拟物和抑制物后HepG2细胞内miR-181a表达、脂质沉积和还原型谷胱甘肽和活性氧水平。通过实时荧光定量PCR和蛋白质印迹法对生物信息学预测的miR-181a靶基因
9岁患儿因反复肝脏生物化学指标异常于2018年5月就诊。诊断为慢性丙型肝炎,GT3a型。给予护肝药物治疗1年余,肝脏生物化学指标始终不能复常。2019年9月索磷布韦获批12岁以下慢性丙型肝炎患儿治疗适应证。患儿于2019年11月起索磷布韦+利巴韦林抗病毒治疗24周。治疗后肝脏生物化学指标复常,HCV RNA转阴,提示治疗效果好。且治疗期间,患儿无不适,监测血常规、肝肾功能均未见异常,提示索磷布韦治疗12岁以下慢性丙型肝炎患儿疗效及安全性均好。